Show simple item record

AuthorNaja, Khaled
AuthorAnwardeen, Najeha
AuthorMalki, Ahmed M.
AuthorElrayess, Mohamed A.
Available date2024-03-30T08:28:34Z
Publication Date2024-02-02
Publication NameFrontiers in Endocrinology
Identifierhttp://dx.doi.org/10.3389/fendo.2024.1313597
CitationNaja, K., Anwardeen, N., Malki, A. M., & Elrayess, M. A. (2024). Metformin increases 3-hydroxy medium chain fatty acids in patients with type 2 diabetes: a cross-sectional pharmacometabolomic study. Frontiers in Endocrinology, 15, 1313597.
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85185146069&origin=inward
URIhttp://hdl.handle.net/10576/53720
AbstractBackground: Metformin is a drug with a long history of providing benefits in diabetes management and beyond. The mechanisms of action of metformin are complex, and continue to be actively debated and investigated. The aim of this study is to identify metabolic signatures associated with metformin treatment, which may explain the pleiotropic mechanisms by which metformin works, and could lead to an improved treatment and expanded use. Methods: This is a cross-sectional study, in which clinical and metabolomic data for 146 patients with type 2 diabetes were retrieved from Qatar Biobank. Patients were categorized into: Metformin-treated, treatment naïve, and non-metformin treated. Orthogonal partial least square discriminate analysis and linear models were used to analyze differences in the level of metabolites between the metformin treated group with each of the other two groups. Results: Patients on metformin therapy showed, among other metabolites, a significant increase in 3-hydroxyoctanoate and 3-hydroxydecanoate, which may have substantial effects on metabolism. Conclusions: This is the first study to report an association between 3-hydroxy medium chain fatty acids with metformin therapy in patients with type 2 diabetes. This opens up new directions towards repurposing metformin by comprehensively understanding the role of these metabolites.
SponsorThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by Qatar National Research Fund (QNRF), grant number NPRP13S-1230-190008.
Languageen
PublisherFrontiers Media SA
Subject3-hydroxy medium chain fatty acids
anti-diabetic drugs
metabolomics
metformin
type 2 diabetes
TitleMetformin increases 3-hydroxy medium chain fatty acids in patients with type 2 diabetes: a cross-sectional pharmacometabolomic study
TypeArticle
Volume Number15
ESSN1664-2392
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record